We have previously demonstrated that the small specific molecule CBP/β-catenin antagonist ICG-001 can inhibit the migration and growth of CSC-enriched NPC tumor spheres via the miRNA-145/SOX2 (SRY-Box Transcription Factor 2) axis [22] and miR-150/CD44 axis [23]. This evidence concerns the gene CREBBP and nasopharyngeal carcinoma.